Non-Hodgkin Lymphoma

Clinical Trials

Below is a list of Non-Hodgkin Lymphoma clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

A Phase Ib Study of SGN-40 (anti-huCD40 mAb) in Combination with Rituximab (Rituxan) and Gemcitabine (Gemzar) for the Treatment of Patients with Relapsed or Refractory (resistant) Diffuse Large B Cell Lymphoma (DLBCL)
Patients are being asked to take part in this research study because they have relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The purpose of this study is to test how well an investigational drug called SGN-40 works in combination with gemcitabine and rituximab, two commonly used drugs for certain types of cancer. The study doctors hope to find out what a safe dose is when these three study drugs are combined, what the side effects are, and whether or not they are an effective combination in treating relapsed or refractory DLBCL. More than 100 people with cancer have received SGN-40 in earlier research studies. These previous research studies were used to evaluate the safety of different doses and schedules of SGN-40 when given on its own.
Read more

A Phase I Study of Weekly Oral ZEN-012, a Small Molecule Anti-Cancer Agent, in Patients With Advanced Cancer and Lymphoma
Patients are being asked to take part in this research study because they have cancer that has continued to grow despite the treatments they may have already received. Either the standard drugs used to treat their disease are no longer working or there are no known treatments that work because the patient's tumor cells may be resistant to these treatments. This clinical trial is about testing ZEN-012 which is a newly discovered chemical compound. It belongs to a group of drugs which may stop tumor cell growth.

This study is being done to:
- Test the safety of ZEN-012 and see what effect (good and bad) it has on the patient and their cancer
- Find the highest dose of ZEN-012 that can be given without causing bad side
effects
Read more

A Phase I Study of Weekly Oral ZEN-012, a Small Molecule Anti-Cancer Agent, in Patients With Advanced Cancer and Lymphoma
Patients are being asked to take part in this research study because they have cancer that has continued to grow despite the treatments they may have already received. Either the standard drugs used to treat their disease are no longer working or there are no known treatments that work because the patient's tumor cells may be resistant to these treatments. This clinical trial is about testing ZEN-012 which is a newly discovered chemical compound. It belongs to a group of drugs which may stop tumor cell growth.
This study is being done to:
- test the safety of ZEN-012 and see what effect (good and bad) it has on the patient and their cancer
- find the highest dose of ZEN-012 that can be given without causing bad side effects.

Read more

A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib (Bay 43-9006) in Combination with the mTOR Inhibitor RAD001 (Everolimus, Certican) in Patients with Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma
Sorafenib and RAD001 are two drugs that block some of the main switch pathways in tumor cells from working properly. When combined, it is hoped that they might prevent the cells from growing or cause them to die. Preliminary experiments with RAD001 in lymphoma patients have shown definite anti-tumor activity.
Read more

Imaging Cells in Monoclonal Antibody Therapy for Lymphoma
This study is being done to learn about how and/or why Rituxan works in the body. It is designed to help to find out how cancer-fighting cells in the body move into the tumor before and after Rituxan is given
Read more

Immunosuppressant, Alefacept (Amevive), in the Treatment of Cutaneous T-Cell Lymphoma and Peripheral T-Cell Non-Hodgkin Lymphoma (LS058C)
This study is being done to test the safety of alefecept (Amevive) and see what effects (good and bad) it has on the patient and lymphoma. The study will find the best dose of alefacept (Amevive) that will produce response in the tumor without causing severe side effects. This research is being done so researchers can find better treatments for people with T-cell lymphoma.
This research study is being done by the Lymphoma SPORE (Specialized Program of Research Excellence). The Lymphoma SPORE is a group of 2 health care centers, Mayo Clinic Rochester and the University of Iowa, that have joined together to research lymphoma and lymphoma treatments. For this study, Mayo Clinic Rochester and the University of Iowa are working with other institutions (City of Hope and John Hopkins) who have been awarded SPORE grants from the NCI. The SPORE is supported by the National Cancer Institute. Mayo Clinic Rochester is the coordinating site for the SPORE.
Read more

N0682, A Phase II Study of Denileukin Diftitox in Combination with Rituximab (Rituxan) in Previously Untreated Follicular B-cell Non-Hodgkin Lymphoma Patients
Patients are being asked to take part in this research study because they have follicular B-cell Non-Hodgkin lymphoma and have not had any chemotherapy or radiation treatment.
This research study is being done to find out what effects, good and/or bad, the drug denileukin diftitox combined with rituximab has on the patient and their follicular B-cell Non-Hodgkin lymphoma.

It is important to realize that while rituximab is frequently used as initial treatment for
this type of lymphoma, chemotherapy is also often used in combination with rituximab as
the first treatment for follicular lymphoma. Treatment with chemotherapy plus rituximab may result in more patients responding to treatment and for a longer time, but also in more side effects.

While doctors hope rituximab and denileukin diftitox will be more useful against cancer compared to rituximab alone or rituximab in combination with chemotherapy drugs, there is no proof of this yet.
Read more

Randomized Phase III Clinical Trial Comparing Outcomes of Immunologic Autograft Engineering Versus Standard Autograft Collection in Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma
This study is being done to:
- Find out what effects (good and bad) the modification of the stem cell collection machine (apheresis machine) has on the collection of lymphocytes (the body immune cells that attack lymphoma).
- To see if collecting more lymphocytes by the new apheresis machine settings will or will not slow, decrease, or stop the growth of the patient's lymphoma.
Read more

SG040-0005, A Randomized, Phase IIb Placebo-controlled Study of RICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for Second-line Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Patients are being asked to take part in this research study to test whether a new drug called SGN-40, added to a commonly used drug combination of antibody (rituximab) and chemotherapy drugs (ifosfamide, carboplatin, and etoposide) called R-ICE, is safe and will improve the outcome for participants with diffuse large B-cell lymphoma (DLBCL) that has relapsed or failed to go away completely after initial treatment.
SGN-40 is a type of drug called a monoclonal antibody (the same type of drug as Rituxan or Mab Thera, which patients have previously received). Monoclonal antibodies are proteins that are designed to attack specific targets on cells. SGN-40 is an antibody which is made from human protein and reacts with a target, CD40, on white blood cells and tumor cells. CD40 is found on almost all DLBCL tumors.
Read more